A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
Public ClinicalTrials.gov record NCT01074008. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 With Ritonavir (ABT-450/r), ABT-333 or ABT-072 Each Administered Alone and in Combination With Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of multiple oral doses of ABT-450/ritonavir (r), ABT-333 (also known as dasabuvir), or ABT-072 in hepatitis C virus (HCV), genotype 1-infected, treatment-naïve adults.
Study identification
- NCT ID
- NCT01074008
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 74 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2010 (Type not available)
- Primary completion
- Jun 2011 (Actual)
- Completion
- Jan 2012 (Actual)
- Last update posted
- Jan 8, 2015
2010 – 2012
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 23392 | Phoenix | Arizona | 85054 | — |
| Site Reference ID/Investigator# 23370 | Anaheim | California | 92801 | — |
| Site Reference ID/Investigator# 23387 | La Jolla | California | 92037 | — |
| Site Reference ID/Investigator# 23388 | Los Angeles | California | 90048 | — |
| Site Reference ID/Investigator# 23371 | Aurora | Colorado | 80045 | — |
| Site Reference ID/Investigator# 23369 | Orlando | Florida | 32803 | — |
| Site Reference ID/Investigator# 26362 | Orlando | Florida | 32809 | — |
| Site Reference ID/Investigator# 23373 | Chicago | Illinois | 60611 | — |
| Site Reference ID/Investigator# 24908 | Chicago | Illinois | 60612 | — |
| Site Reference ID/Investigator# 23381 | Indianapolis | Indiana | 46202-5121 | — |
| Site Reference ID/Investigator# 23372 | Baton Rouge | Louisiana | 70810 | — |
| Site Reference ID/Investigator# 24710 | New Orleans | Louisiana | 70112 | — |
| Site Reference ID/Investigator# 23391 | Baltimore | Maryland | 21287 | — |
| Site Reference ID/Investigator# 23377 | Detroit | Michigan | 48202 | — |
| Site Reference ID/Investigator# 24909 | Saint Paul | Minnesota | 55114 | — |
| Site Reference ID/Investigator# 35842 | New York | New York | 10016 | — |
| Site Reference ID/Investigator# 23379 | New York | New York | 10021 | — |
| Site Reference ID/Investigator# 23375 | Chapel Hill | North Carolina | 27599-7584 | — |
| Site Reference ID/Investigator# 23385 | Durham | North Carolina | 27705 | — |
| Site Reference ID/Investigator# 23376 | Dallas | Texas | 75203 | — |
| Site Reference ID/Investigator# 24891 | Houston | Texas | 77030 | — |
| Site Reference ID/Investigator# 23382 | San Antonio | Texas | 78215 | — |
| Site Reference ID/Investigator# 24715 | Salt Lake City | Utah | 84132-2410 | — |
| Site Reference ID/Investigator# 25463 | Seattle | Washington | 98101 | — |
| Site Reference ID/Investigator# 23383 | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01074008, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2015 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01074008 live on ClinicalTrials.gov.